



Press Release

MediVision Medical Imaging Ltd.

☎ + (972) 4-989-4884

☎ + (972) 4-989-4883

✉ P.O. Box 45, Yokneam Elit Kenyon Drachim 20692, Israel

📧 noam@medivision-ois.com

FOR IMMEDIATE RELEASE

MediVision sells 310,000 Shares of Ophthalmic Imaging Systems Common Stock at a price per share of \$1.45

Yokneam Elit, Israel, MediVision Medical Imaging Ltd. (the "Company") (EURO.NM: MEDV) a leading provider of ophthalmic digital imaging systems for the ophthalmology market, announced today (December 19, 2005) that it sold 310,000 of the Company's holdings in its American subsidiary, Ophthalmic Imaging Systems (OTCBB: OISI) ("OIS") to Bard Associates, Inc. in consideration for \$1.45 per share.

Following this sale of equity MediVision's current holding in OIS will be reduced to 68%. As a result of this transaction, Medivision is expected to show a capital gain in the financial statement of the fourth quarter of 2005.

Bard Associates manages the Bard Micro-cap Value Fund, L.P. as well as other value portfolios for individuals. The firm primarily invests in micro/small-cap U.S. stocks with market capitalization less than \$300 million

Mr. Noam Allon Chief Executive Officer of MediVision Medical Imaging Ltd, said, "The sale of shares is part of capital raising activities which are carried out continuously and are focused primarily on strategic growth. The funds will provide us with additional working capital to support our business expansion and growth. With this transaction and similar previous transactions which we performed during September 2005 and during FY2004, we succeeded in attracting to OIS investors that possess a solid knowledge of small-cap equities. We believe it is an additional step towards increasing the awareness of the market and the investment community in both OIS and MediVision. As a result of the agreement, the public float of OIS share will increase to approximately 5.1 million shares."

About MediVision

MediVision specializes in digital imaging devices for ophthalmic applications with an emphasis on diagnostics related to the eye retina. MediVision's products are designed to provide digital upgrades for a range of ophthalmic imaging systems, thus significantly enhancing imaging capability and providing its users with advanced diagnostic tools. The company has significant market share and is a market leader in the ophthalmic digital imaging field. The Company owns 68% interest in Ophthalmic Imaging Systems Inc. based in Sacramento, California, USA. The Company holds 63% interest in CCS Pawlowski GmbH. Based in Jena, Germany.

This Release contains certain forward-looking statements and information relating to the Company that are based on the beliefs of the Management of the Company as well as assumptions made by and information currently available to the Management of the Company. Such statements reflect the current views of the Company with respect to future events, the outcome of which is subject to certain risks and other factors, which may be outside of the Company's control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results of outcomes may vary materially from those described herein as projected, anticipated, believed, estimated, expected or intended.

End of message

For more information, please contact:

Noam Allon

MediVision Medical Imaging Ltd.

President, Chief Executive Officer

Tel. ++972-4-9894884

Fax ++972-4-9894883

Noam@medivision-ois.com